Mounjaro pen doses: choosing the right strength for you

The decision you're actually facing at each pen change

Most people come to this question at one of two moments: they've just been prescribed Mounjaro and are surprised the first pen is so low, or they're a few months in and wondering whether they should be on a higher strength by now. Both are reasonable things to wonder about.

The six Mounjaro pen strengths follow a licensed titration pathway described in the prescribing information on the Mounjaro SmPC on the eMC. The path runs 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg, with a minimum of four weeks at each level before moving up. But the schedule is a ceiling, not a timetable. If side effects are notable at a given strength, staying put for longer is often the right call. If you've reached a dose that's working well and tolerating fine, your prescriber may choose to maintain it rather than push further. The highest strength isn't a goal; effective, sustainable treatment is.

This is worth sitting with: tirzepatide is a dual GIP and GLP-1 receptor agonist, the only weight-loss medicine of its kind licensed in the UK, and it acts on appetite, fullness and gastric emptying simultaneously. The clinical effects build across weeks, which is precisely why dose decisions need time and evidence behind them, not impatience.

What the 2.5 mg pen is actually for

The starter pen exists for one reason: to let your body get used to the medicine before any meaningful therapeutic effect is expected. Gastrointestinal side effects (nausea, loose stools, indigestion) are most likely in the first weeks or after a dose increase, and starting low reduces that risk considerably. That's the job of the first pen. Weight change at 2.5 mg is typically modest, and that's by design.

It's worth checking the dose window on your pen before every injection, just a five-second habit that confirms you're using the right strength and that the pen is within its storage timeline. It takes less time than unlocking your phone.

Some people feel tempted to stay at 2.5 mg longer than planned because it feels manageable. Others want to move up as fast as possible. Neither instinct is automatically right. The question your prescriber is asking is: has your system settled enough to tolerate the next step? Our page on staying on 2.5 mg Mounjaro covers that specific situation in more depth if it's where you are.

How many doses each pen holds, and why that matters for planning

Every Mounjaro pen, regardless of strength, contains four doses. One pen, one month. That's a practical fact worth knowing early, because it shapes how you plan supply and repeats. If a pen is damaged, dropped, or a dose is administered incorrectly, you're not dealing with a daily medicine where you can simply take tomorrow's, each pen represents a month of treatment.

The full breakdown of how many doses are in a Mounjaro pen explains the pen mechanics in more detail, including what happens if you use a dose incorrectly. For now, the short version: four fixed doses per pen, delivered once weekly, with the pen discarded (safely, in a sharps container) after the fourth injection.

Knowing this also answers a common practical question about cost. Because the dose range spans six strengths, the monthly cost of treatment does vary by pen, higher strengths carry different list prices. If you want a closer look at how this plays out specifically at the 5 mg level, you can read more about Mounjaro 5 doses and what to expect at that stage. Understanding that structure helps you plan for the longer term, rather than being caught out when titration moves you to the next pen.

When a prescriber considers the full 15 mg range (and what the evidence shows

The SURMOUNT-1 trial, published in the New England Journal of Medicine, found that adults taking tirzepatide at the highest doses lost an average of around 20–21% of body weight over 72 weeks) figures that shaped NICE's decision to recommend tirzepatide for eligible adults in England. NICE's appraisal (TA1026, published December 2024) sets out who qualifies under NHS criteria, though private treatment follows the licensed SmPC eligibility rather than the narrower NHS thresholds.

Not everyone reaches 15 mg, and not everyone needs to. Some people find a lower maintenance dose effective and well-tolerated, and staying there is entirely legitimate. The clinical question is always: what is the right dose for this person, at this point? That's why repeat prescriptions at nume involve a clinical review every time, a real prescriber, not a form auto-renewing. If you're specifically wondering how the pen works at the 5 mg strength, our guide to the 5 doses in a Mounjaro pen walks through the practicalities in detail. If you want to understand the evidence behind the higher doses in more detail, the Mounjaro treatment overview covers the trial data alongside how the medicine works.

If you're trying to work out whether you're a candidate for private treatment and want a prescriber to assess your situation properly, checking your eligibility through a free consultation is the sensible next step.